openFDA
Cure8 regulatory brief
Rowasa FDA label update (2026-08-03)
Medications
Mesalamine
Aminosalicylates
Abdominal Pain
Flare
Regulatory Update
Adult patients
Clinicians
Why This Matters
This label update restates safety information for ROWASA (a mesalamine rectal formulation) used for distal ulcerative colitis. Patients with IBD should be aware of potential serious hypersensitivity reactions, kidney and liver risks, and symptoms that can resemble a flare.
Who Should Pay Attention
Adults with distal ulcerative colitis using or considering ROWASA, clinicians prescribing or monitoring mesalamine therapies, and caregivers monitoring for adverse reactions.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
ROWASA (mesalamine rectal) label information updated.
The label lists indications for active mild to moderate distal ulcerative colitis, proctosigmoiditis, and proctitis in adults and emphasizes multiple warnings and precautions including sulfite-related hypersensitivity (potassium metabisulfite), renal impairment monitoring, mesalamine-induced acute intolerance syndrome with symptoms that can mimic an IBD flare, hepatic concerns, severe cutaneous adverse reactions (SJS/TEN/DRESS/AGEP), photosensitivity, and nephrolithiasis.
The label advises assessing renal function at baseline and periodically, discontinuing ROWASA if renal function worsens or if acute intolerance or severe hypersensitivity is suspected, and ensuring adequate hydration because mesalamine-containing stones may not be visible on standard imaging.
The update is a regulatory drug-label record from DailyMed (FDA/openfda). It is a product labeling document rather than a clinical study; the content reflects approved prescribing information, safety warnings, and monitoring recommendations. Read the full label or discuss with your clinician for how these warnings apply to your situation.
Keep In Mind
This is an FDA DailyMed regulatory drug label (structured regulatory-record). It provides prescribing and safety guidance; it is not a clinical trial report. For personal medical decisions, consult your prescribing clinician.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorViatris Specialty LLC
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedAug 3, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Case of Elderly-Onset Ulcerative Colitis with Large-Vessel Giant Cell Arteritis Treated Successfully with Tofocitinib.
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
Transient sinus bradycardia complicating acute severe ulcerative colitis a case report and review of the literature
Severe ulcerative colitis can be linked to rare cardiac rhythm disturbances; recognizing bradycardia during flares may prompt appropriate evaluation and monitoring. The case signals clinicians to consider cardiac causes...
mesalamine FDA label update (2026-07-14)
This label update lists safety concerns that affect people taking mesalamine for ulcerative colitis, including the need for kidney monitoring, signs of hypersensitivity, and rare but serious skin and liver reactions.